Endo Pharma to withdraw application for new opioid painkiller formulation #the #pharmaceutical #industry


Posted On Aug 13 2017 by

#endo pharma

#

Endo Pharma to withdraw application for new opioid painkiller formulation

Endo Pharmaceuticals PLC has decided to withdraw its supplemental new drug application for the extended-release version of its Opana opiod painkiller but said it would continue to work with the U.S. Food and Drug Administration to advance the drug.

Shares in the company ENDP, -2.03% added 2.4% to $23.55 in premarket trading.

The pharmaceutical company, which is domiciled in Dublin and has U.S. headquarters in Malvern, Pa. plans to continue collecting and analyzing data on the drug and could refile.

“We anticipate the generation of additional data, and we will seek collaboration with FDA to appropriately advance Opana ER,” said Dr. Sue Hall, global head of research and development and quality at Endo.

Opana ER, one of Endo’s biggest selling brand-name drugs, has been facing generic competition. During the first quarter, sales of Opana ER declined 4.7% to $44.7 million and comprised roughly 14% of Endo’s U.S. branded drug revenue and a third of sales in its pain-management segment.

Copyright 2016 MarketWatch, Inc. All rights reserved.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.

Stocks

Columns

Authors

Topics

No results found

LatestNews





Last Updated on: August 13th, 2017 at 6:52 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *